LQT-1213 is a first-in-class serum glucocorticoid regulated kinase 1 inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LQT-1213, a first-in-class serum ...

Please provide your email address to receive an email when new articles are posted on . In long QT syndrome, patients doing vigorous exercise did not have more events than those doing nonvigorous ...

Please provide your email address to receive an email when new articles are posted on . In people with long QT syndrome, vigorous exercise did not raise risk for death or arrhythmias vs. nonvigorous ...

A machine learning model was more effective at detecting congenital long QT syndrome on resting ECGs than manual measurement of QT intervals by arrhythmia experts, in a new study. Researchers ...

FRESNO, Calif. (KFSN) -- The discovery of a heart condition in young people used to mean "benching" from them sports for good. But doctors have found a way to keep kids in the game, despite their ...

An innovative analysis of shared segments within the genome - an indication of distant "relatedness" - has identified undiagnosed cases of Long QT syndrome, a rare disorder that can lead to abnormal ...

Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2. Wave II is informed by the successful Wave I clinical study with LQT-1213 and ...

Q: I recently read that long QT syndrome is quite common. What is it, and how is it diagnosed? I have read that fainting may be one sign of the disorder. Can long QT syndrome be treated? A: Long QT ...

In many low- and middle-income countries, pediatric cardiologists can't help children with congenital heart conditions because of a critical hurdle. They don't have easy access to advanced diagnostic ...